Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors

類似資料

• Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies
  著者:: Ruiz‐Garcia, Ana, 等
  出版事項: (2020)
• An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure
  著者:: Lin, Swan, 等
  出版事項: (2020)
• Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30‐Expressing Hematologic Malignancies
  著者:: Li, Hong, 等
  出版事項: (2017)
• Population Pharmacokinetics and Exposure‐Response Analyses for CPX‐351 in Patients With Hematologic Malignancies
  著者:: Wang, Qi, 等
  出版事項: (2018)
• Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors
  著者:: Yin, Ophelia, 等
  出版事項: (2020)